Hey, I hear you and I'm hoping for the same. I'd
Post# of 148182
A bigger or better deal, with a bigger or better partner, is simply moving the carrot unless they can PR an NBA with the name of the partner and the terms. The exposure in that case would be worth it, because saying that you have an NBA for an $XXX million (billion?) deal with (Bayer? Gilead? Merck?) would provide the exposure to likely move the share price and allow them to fund at more acceptable levels.
I expect only to hear an update on the FDA dose selection and some smoke about needing to be careful and exploring options with new partners based on new data. I hope I'm wrong, but empirical evidence calls it smart money at this point.